Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Pharmaceutical companyLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field. in United StatesLabelled by claude-haiku-5.5 from the firm's FDA names. It is not an FDA field.. FDA records under its name, each linked to the record.
As of Nov 14, 2026, FDA's public records list Corcept Therapeutics and its 1 subsidiaries with 2 drug applications and 1 complete response letter. The most recent is a complete response letter dated Jan 28, 2026: Complete response letter, NDA 219398.
Group recordsLabelled by a language model (which subsidiaries belong to the group) from the firm's FDA names. It is not an FDA field.: 3, 2 entities
Drug applications: 2
Complete response letters: 1
Records by Year
Drug approvals, 510(k) clearances, recalls and letters, 2017 to 2026 to date, Corcept Therapeutics and its 1 subsidiaries
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
02017Records0
020182018Records0vs 2017+0
02019Records0vs 2018+0
020202020Records0vs 2019+0
02021Records0vs 2020+0
020222022Records0vs 2021+0
02023Records0vs 2022+0
020242024Records0vs 2023+0
02025Records0vs 2024+0
220262026 to dateRecords2
Latest Records
Newest first across sources; each opens the record
What this company reported paying US doctors and teaching hospitals each year; see every company
2025: $8.2MGeneral $5.5M · Research $0.5M · Ownership $2.2M
2024: $4.2MGeneral $3.9M · Research $0.3M
2023: $3.2MGeneral $2.2M · Research $1.0M
2022: $1.6MGeneral $1.6M · Research $0.0M
2021: $9.1MGeneral $1.5M · Research $7.6M · Ownership $0.0M
2020: $6.3MGeneral $0.9M · Research $5.0M · Ownership $0.5M
2019: $4.8MGeneral $1.4M · Research $3.4M
Orphan Designations (FDA)
5 designations since 1983, 1 approved for the designated use, matched by the sponsor's name; see all orphan designations
dazucorilantTreatment of amyotrophic lateral sclerosis · Aug 18, 2020
relacorilantTreatment of endogenous Cushing syndrome · Oct 15, 2018
relacorilantTreatment of Pancreatic Cancer · Sep 27, 2018
mifepristoneTreatment of ovarian cancer. · Jan 14, 2016
KorlymTreatment of the clinical manifestations of endogenous Cushing's syndrone · Jul 5, 2007 · approved Feb 17, 2012
Names and Identifiers
Appears as
CORCEPT THERAP
Spellings are joined only when they reduce to the same name, or a reviewed source names the same company. Sharing an FDA establishment number (FEI) is not enough: contract sites make products for many firms. Facts marked AI were labelled by a language model from the firm's FDA names; everything else comes from FDA or Wikidata.How this page is built
